NCT06135493

Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients

Efficacy of Losartan in the Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 84 (actual)
• Sponsor: Future University in Egypt · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Paclitaxel-induced peripheral neuropathy (PIPN) is one of the most dose-limiting side effects; it causes patients discomfort and pain and sometimes causes the termination of the chemotherapy cycles, leading to treatment failure. A lot of interventions have been tried to prevent PIPN, ensure complete administration of the chemotherapy cycles, and increase the survival rate. One of the promising interventions in the prevention of PIPN is Losartan. Losartan is an angiotensin receptor blocker (ARBs) and is used to treat hypertensive patients. There is strong evidence from different preclinical studies and retrospective cohort studies that Losartan has a neuroprotective effect. The purpose of our study is to investigate the efficacy of Losartan in the prevention of peripheral neuropathy associated with Paclitaxel treatment in Breast Cancer patients.

Conditions

• Peripheral Neuropathy Due to Chemotherapy

Interventions

Type	Name	Description
DRUG	Losartan	Using losartan to prevent paclitaxel-induced peripheral neuropathy

Timeline

• Start date: 2023-12-12
• Primary completion: 2025-03-30
• Completion: 2025-03-30
• First posted: 2023-11-18
• Last updated: 2025-04-24

Locations

1 site across 1 country: Egypt